# of Displayed Technologies: 10 / 13

Applied Category Filter (Click To Remove): Therapeutics


Categories

Engineered Cells for Treatment of Animal Metabolic Disorders
TS-041976 — The implantation of engineered thermogenic cells for treating metabolic disease and obesity in animals.
Obesity remains one of the main underlying causes for many malignancies in domestic animals such as cats, dogs, and horses. From a veterinary perspective, obesity dramatically increases the risk of cancer, one of the leading causes of death in domesticated animals. Other diseases correlated with o…
  • College: College of Education & Human Ecology
  • Inventors: Ziouzenkova, Ouliana
  • Licensing Officer: Flammang, Ann Marie

Method to improve efficiency and specificity of human tumor targeting and elimination by using a combination of split & splice protein toxins and oncolytic viruses
TS-040838 — Novel strategy to improve efficiency and specificity of tumor treatment via combinative use of a split & splice protein toxin and oncolytic virus.
In combating malignancies as complex as cancer, researchers and clinicians have created a diverse set of strategies to reduce tumor burden. Oncolytic viruses (OVs) have emerged as a promising means of treating this disease due to their potential to selectively target and effectively kill cancer ce…
  • College: College of Arts & Sciences
  • Inventors: Kudryashov, Dmitri; Kudryashova, Elena
  • Licensing Officer: Flammang, Ann Marie

Novel compositions of nanoparticles for nucleic acid therapeutic delivery
TS-040254 — Novel lipid-based nanoparticles that utilize a surfactant to improve self-assembly and stability. Finalized particles can be used for delivery of nucleic acids such as oligonucleotides and plasmid DNA.
Lipid-based nanoparticles (LNPs) have been extensively utilized in nucleic acid delivery. However, there are a number of challenges associated with LNP formulation. It is difficult to make sub-100-nm LNPs with a high nucleic acid concentration by traditional self-assembly methods. LNP synthesis ty…
  • College: College of Pharmacy
  • Inventors: Lee, Robert
  • Licensing Officer: Flammang, Ann Marie

Treatment of Multiple Sclerosis with small molecule IL-6/STAT3 inhibitors
TS-038701 — Small-molecule prodrugs that target IL-6/STAT3 signaling pathway.
Multiple Sclerosis (MS), an unpredictable and disabling autoimmune disease affecting the central nervous system, is the leading cause of non-traumatic neurological disability in young adults. There have been important advances in MS therapy, such as drugs that slow the progression of the disease a…
  • College: College of Medicine (COM)
  • Inventors: Yang, Yuhong; Li, Chenglong; Racke, Michael
  • Licensing Officer: Flammang, Ann Marie

Use of Gene Product to Treat Nerve Injury and Sarcopenia
TS-037778 — A novel method using the overexpression of survival motor neuron protein to improve motor unity synaptic repair and restore/protect muscle size and function due to sarcopenia
Sarcopenia, the age-related wasting and loss of strength, is an important neuromuscular problem of aging. It affects up to 50% of individuals by the 8th decade, and can lead to impaired mobility, loss of independence, and increased risk of mortality. The neuromuscular system is comprised of groups…
  • College: College of Medicine (COM)
  • Inventors: Burghes, Arthur; Arnold, William; Kaspar, Brian; McGovern, Vicki
  • Licensing Officer: Flammang, Ann Marie

Thermogenic Compositions and Methods
TS-037747 — Biologicals for treatment of obesity related disease, including glucose intolerance and neurological disorders.
Worldwide obesity has tripled over the last 40 years and the incidence of overweight or obese populations is rising in low, middle, and high income countries. An increase in adipose tissue results in higher risk for cardiovascular disease and type 2 diabetes, which increase risk for Alzheimer&rsqu…
  • College: College of Education & Human Ecology
  • Inventors: Ziouzenkova, Ouliana; Parquette, Jonathan
  • Licensing Officer: Flammang, Ann Marie

Antisense Oligonucleotide Development for Treatment of Spinal Muscular Atrophy
TS-037741 — The SMN2 gene contains sequences that regulate the level of inclusion of SMN exon7 in SMN mRNA, and some of these act in a negative manner. Antisense oligonucleotides to block the negative regulating protein binding to these sites can increase inclusion of SMN exon 7 and thus, the amount of SMN being produced.
Spinal muscular atrophy (SMA) is a genetic disorder that affects the control of muscle movement. It is caused by a loss of motor neurons in the spinal cord and brainstem, leading to weakness and atrophy in the muscles used for walking, crawling, sitting up, and head movement. In severe instances, …
  • College: College of Medicine (COM)
  • Inventors: Burghes, Arthur; McGovern, Vicki; Prior, Thomas
  • Licensing Officer: Flammang, Ann Marie

Phyllanthusmin and acutissimalignan A compound derivatives for anticancer and immunostimulation
TS-037721 — A group of potential antitumor arylnapthalene lactone derivatives, which may be developed as novel anticancer and immunostimulant agents.
Natural products and semi-synthetic derivatives derived from them have been used for anticancer drugs or drug leads for many years. However, side-effects such as myelosuppression and secondary leukemia have been reported. Furthermore, these natural products can be difficult to use for targeting sp…
  • College: College of Pharmacy
  • Inventors: Kinghorn, Alan "Dr. A. Douglas Kinghorn"; Fuchs, James; Huntsman, Andrew
  • Licensing Officer: Flammang, Ann Marie

STAT3 Inhibitors and Their Anti-Cancer Usage
TS-037671 — Novel non-peptidomimetic molecules for use as anti-cancer inhibitors of signal transducer and activator of transcription 3.
The search for more potent drug delivery candidates for cancer therapy remains a challenge within the medical community. Efforts to target cancer at the genetic level have led to numerous discoveries, including the role that constitutive activation of signal transducer and activator of transcripti…
  • College: College of Pharmacy
  • Inventors: Li, Chenglong; Lin, Jiayuh; Yu, Wenying
  • Licensing Officer: Flammang, Ann Marie

Antisense Morpholino Treatment to Increase SMN Levels and Treat Spinal Muscular Atrophy
TS-037648 — A treatment for spinal muscular atrophy.
Spinal Muscular Atrophy (SMA) is caused by deletion or mutation of SMN1 and retention of SMN2, this in turn leads to reduced levels of the full SMN protein. SMA is the second leading cause of neuromuscular disease, and many people living with SMA need round-the-clock care from their families and a…
  • College: College of Medicine (COM)
  • Inventors: Burghes, Arthur; Porensky, Paul
  • Licensing Officer: Flammang, Ann Marie

Show More Technologies

PDF

Loading icon